期刊文献+

Effects of angiotensin converting enzyme inhibitor,angio-tensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats 被引量:13

Effects of angiotensin converting enzyme inhibitor,angio-tensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats
原文传递
导出
摘要 Background Transforming growth factor (TGF) β1-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin Ⅱ type Ⅰ receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg · kg^-1· d^-1), ARB group (irbesartan 50mg · kg^-1· d^-1), ACEI+ARB group (benazepril 10 mg · kg^-1· d^-1+irbesartan 50 mg · kg^-1· d^-1) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight (VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGFβ1, Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P〈0.01). This increase was limited in ACEI, ARB, and combined groups (P〈0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68±0.5)% compared with that in control group (P〈0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 ± 0.5)%, (3.5 ± 0.5)%, (3.2± 0.4)%] in comparison with that in placebo group (P〈0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P〈0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P〈0.01 compared with placebo group). The mRNA expression of TGFβ1, Smad 2, and Smad 3 (0.700±0.045, 0.959±0.037 and 0.850±0.051) increased in placebo group compared with that in control group (P〈0.01). ACEI, ARB and combined treatment normalized the increase (P〈0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF β1 and Smad mRNA expression than ACEI treatment (P〈0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P〈0.01). ACEI, ARB and combined treatment normalized the increase (P〈0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P〈0.01).Conclusions TGFβ1-Smads signal activation is correlated With ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3. ARB and combined treatment are more effective than ACEI alone. Background Transforming growth factor (TGF) β1-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin Ⅱ type Ⅰ receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg · kg^-1· d^-1), ARB group (irbesartan 50mg · kg^-1· d^-1), ACEI+ARB group (benazepril 10 mg · kg^-1· d^-1+irbesartan 50 mg · kg^-1· d^-1) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight (VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGFβ1, Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P〈0.01). This increase was limited in ACEI, ARB, and combined groups (P〈0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68±0.5)% compared with that in control group (P〈0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 ± 0.5)%, (3.5 ± 0.5)%, (3.2± 0.4)%] in comparison with that in placebo group (P〈0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P〈0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P〈0.01 compared with placebo group). The mRNA expression of TGFβ1, Smad 2, and Smad 3 (0.700±0.045, 0.959±0.037 and 0.850±0.051) increased in placebo group compared with that in control group (P〈0.01). ACEI, ARB and combined treatment normalized the increase (P〈0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF β1 and Smad mRNA expression than ACEI treatment (P〈0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P〈0.01). ACEI, ARB and combined treatment normalized the increase (P〈0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P〈0.01).Conclusions TGFβ1-Smads signal activation is correlated With ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3. ARB and combined treatment are more effective than ACEI alone.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2006年第8期649-655,共7页 中华医学杂志(英文版)
基金 The project was supported by a grant from the Natural Science Foundation of Heilongjiang Province (No. D0239) and the Post Doctor Foundation of Heilongjiang Province.
关键词 SMAD ventricular remodeling angiotensin converting enzyme inhibitor angiotensin II type I receptor blocker Smad ventricular remodeling angiotensin converting enzyme inhibitor angiotensin II type I receptor blocker
  • 相关文献

参考文献10

  • 1Pinto YM,Pinto-Sietsma SJ,Philipp T,Engler S,Kobetamehl P,Hocher B,et al.Reduction in left ventricular messenger RNA for transforming growth factor β 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR (mRen2) 27 Rat[].Journal of Hypertension.2000
  • 2Swedberg K,Pfeffer M,Granger C,Held P,McMurray J,Ohlin G,et al.Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design.Charm-Programme Investigators[].Journal of Cardiac Failure.1999
  • 3Sutton MG,Sharpe N.Left ventricular remodeling after myocardial infarction: pathophysiology and therapy[].Circulation.2000
  • 4Ammarguellat F,Larouche L,Schiffrin EL.Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism[].Circulation.2001
  • 5Nakamura Y,Yoshiyama M,Omura T,Yoshida K,Izumi Y,Takenchi K,et al.Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction[].Cardiovascular Research.2003
  • 6Cohn JN,Tognoni G,Glazer R,Spormann D.Baseline demographics of the Valsartan Heart Failure Trial.Val-HeFT Investigators[].European Journal of Heart Failure.2000
  • 7Sun Y,Zhang J,Zhang JQ,Ramires FJ.Local angiotensin Ⅱand transforming growth factor-β1 in renal fibrosis of rats[].Journal of Hypertension.2000
  • 8TAOZe-wei,HUANGYuan-wei,XIAQiang,XUQi-wen.Combined effects of ramipril and angiotensin Ⅱ receptor blocker TCV116 on rat congestive heart failure after myocardial infarction[J].Chinese Medical Journal,2005(2):146-154. 被引量:19
  • 9Hao J,Wang B,Jones SC,Jassal DS,Dixon IMC.Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro[].American Journal of Physiology Heart and Circulatory Physiology.2000
  • 10Velazquez EJ,Pfeffer MA,McMurray JV.VALsartan in acute myocardial infarction (VALIANT) trial: baseline characteristics in context[].European Journal of Heart Failure.2003

二级参考文献10

  • 1KramerCM,FerrariVA,RogersWJetal.Angiotensin convertingenzymeinhibitionlimitsdysfunctioninadjacentnoninfarctedregionsduringleftventricularremodeling[].Journal of the American College of Cardiology.1996
  • 2SeeS,StirlingAL.Candesartancilexetil: anangiotensinⅡ receptorblocker[].AmJHealthSystPharm.2000
  • 3TaoZW,HuangYW,XiaQetal.Earlyassociationofelectrocardiogramalterationwithinfarctsizeandcardiacfunctionaftermyocardialinfarction[].JZhejiangUnivSci.2004
  • 4ShenYT,WiedmannRT,GreenlandBDetal.CombinedeffectsofangiotensinconvertingenzymeinhibitionandangiotensinⅡreceptorantagonisminconsciouspigswithcongestiveheartfailure[].Cardiovascular Research.1998
  • 5YoshidaK,XuHL,KawamuraTetal.Chronicangiotensin convertingenzymeinhibitionandangiotensinⅡantagonisminratswithchronicrenalfailure[].JCardiovascPharmacol.2002
  • 6DendorferA,WolfrumS,DominiakP.Pharmacologyandcardiovascularimplicationsofthekinin kallikreinsystem[].Japanese Journal of Pharmacology.1999
  • 7TschopeC,GohlkeP,ZhuYZetal.Antihypertensiveandcardioprotectiveeffectsafterangiotensin convertingenzymeinhibition: roleofkinins[].JCardFail.1997
  • 8KojiT,OnishiK,DohiKetal.AdditionofangiotensinⅡreceptorantagonisttoanACEinhibitorinheartfailureimprovescardiovascularfunctionbyabradykinin mediatedmechanism[].JCardiovascPharmacol.2003
  • 9BorderWA,RuoslahtiE.Transforminggrowthfactor betaindisease: thedarksideoftissuerepair[].The Journal of Clinical Investigation.1992
  • 10KimS,OhtaK,HamaguchiAetal.AngiotensinⅡtypeIreceptorantagonistinhibitsthegeneexpressionoftransforminggrowthfactor beta1 andextracellularmatrixincardiacandvasculartissuesofhypertensiverats[].Journal of Pharmacology and Experimental Therapeutics.1995

共引文献18

同被引文献62

引证文献13

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部